I'd also add it's a high beta stock getting crunched in line with the market downturn.
Check out Capricor Therapeutics - 20% rise yesterday off the back of partnering with a dominant Japanese pharma player. Just another sign of the exosome market heating up and it augurs well for our preliminary partnership with Showa Denko (also Japanese). Finally, on the academic/research side, over 400 exosome papers have been published in 2022 so far, which represents strong growth relative to the ~9000 papers in 2021.
I'd also add it's a high beta stock getting crunched in line...
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
